By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


EyeGate Pharma 

100 Beaver Street

Waltham  Massachusetts  02453-8425  U.S.A.
Phone: 781-788-8869 Fax:


Medical Device

Company News
EyeGate Pharma Names Michael B. Raizman, MD, Consulting Chief Medical Officer 3/2/2015 7:56:25 AM
EyeGate Pharma Announces Closing Of Initial Public Offering Of Approximately $4,100,000 Of Common Stock 2/20/2015 7:14:24 AM
EyeGate Pharma Prices $4,100,000 Initial Public Offering 2/13/2015 7:45:48 AM
EyeGate Pharma Postpones $25 Million IPO 10/3/2014 6:23:50 AM
EyeGate Pharma's EGP-437 Matches the Standard-of-Care's Response Rate in Phase III Study in Patients With Anterior Uveitis 4/9/2013 11:40:38 AM
EyeGate Pharma Enrolls Last Patient in Pivotal Phase III Anterior Uveitis Study of EGP-437 12/18/2012 8:45:33 AM
EyeGate Pharma Initiates Phase III Study of EGP-437 in Patients With Anterior Uveitis 1/5/2012 9:06:00 AM
EyeGate Pharma Secures Additional $5.9M Series D Venture Funding 1/5/2011 6:42:21 AM
EyeGate Pharma Awarded Grants Totaling Nearly $1 Million by United States Government Section 48D Therapeutic Discovery Program 11/4/2010 9:15:13 AM
RXi Pharmaceuticals (RXII) and EyeGate Pharma Announce Collaboration Focused on Non-Invasive Ocular Delivery of RNAi Therapeutics 9/22/2010 9:56:16 AM